The goal of this clinical trial is to learn if a novel intraoperative fluorescence-guided system (EndoSCell Scanner) can help surgeons more accurately remove all cancerous tissue during breast-conserving surgery in female patients aged 18 years or older, with primary breast cancer. The main questions it aims to answer are: * Does the use of the EndoSCell Scanner system lower the rate of secondary surgeries needed due to positive cancer margins after the initial operation? * How accurate is the EndoSCell Scanner system in detecting residual cancer cells on the walls of the surgical cavity during the operation? Researchers will compare the surgical outcomes using the EndoSCell Scanner guidance to the expected outcomes from standard surgical practice without this technology to see if the system is effective. Participants will: * Receive their planned breast-conserving surgery (lumpectomy). * Have their surgical cavity scanned with the EndoSCell Scanner device after the main tumor is removed. * Have additional tissue removed from the cavity wall if the scanner indicates a potential cancer residue.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Enrollment
172
The EndoSCell Scanner (ES Scanner) is an intraoperative fluorescence imaging system used during breast-conserving surgery to provide real-time, cellular-level visualization of the surgical cavity wall. During the surgery, after removing the main tumor specimen and the standard circumferential cavity shave margins, the cavity wall is locally stained with sodium fluorescein and methylene blue. Then, the ES Scanner probe is placed on the cavity wall tissue and the blue light is used to detect the fluorescence patterns related to residual cancer cells. The system processes and displays these images in real time, highlighting the areas that may contain residual cancer cells. This visual guidance aims to assist surgeons in precisely removing additional tissue margins ( "therapeutic shaves" ) from specific suspicious cavity wall locations during the initial surgery, in order to achieve a negative (no cancer) surgical margin in the first operation.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The rate of positive margins on final pathological testing
Positive margins were defined as tumor touching the edge of the specimen that was removed in patients with invasive cancer and tumor that was within 2 mm of the edge of the specimen removed in those with ductal carcinoma in situ.
Time frame: From the date of the initial lumpectomy (Day 0) until the receipt of the final postoperative pathology report and surgical decision, assessed up to 30 days post-surgery.
Reexcision rates
defined as the proportion of patients who were returned to the operating room for further surgery for margin clearance. Although it was expected that surgeons would perform reexcision on patients whose final margin was positive, this decision was left to the surgeons' discretion.
Time frame: From the date of secondary surgery until receipt of its final pathology report, assessed up to 60 days post-initial surgery.
Mean Absolute Volume of Therapeutic Shave Tissue
The average volume (in cubic centimeters, cc) of tissue excised as ES Scanner-guided Therapeutic Shaves (T-shaves) per participant. Volume calculation for each T-shave: length (cm) × width (cm) × depth (cm). The total T-shave volume per participant is the sum of all individual T-shave volumes. For participants who did not undergo T-shave excision, the volume is recorded as 0 cc.
Time frame: Intraoperative. Measured immediately after tissue excision
Mean Proportion of Therapeutic Shave Volume to Total Resection Volume
The average percentage contribution of the T-shave volume to the total volume of all tissue resected during the initial surgery. Calculation: (T-shave volume) / (Main specimen volume + SOC shave volume + T-shave volume) × 100%.
Time frame: Intraoperative. Calculated after all tissue from the initial surgery is measured
Patient-reported outcome /PRO
The patients reported the postoperative cosmetic effect using the BREAST-Q Breast-Conserving Therapy Module. The scoring range of each sub-scale in this module (such as satisfaction, quality of life, etc.) is from 0 to 100 points, with a minimum of 0 and a maximum of 100. Higher scores always mean better results. A score of 100 represents the possible best state (such as the most satisfactory or the highest quality of life), while a score of 0 represents the possible worst state.
Time frame: 90 ± 7 days post-initial surgery
Record of Intraoperative Device Issues or Malfunctions
The frequency, type, and impact (e.g., on data acquisition, procedural continuity) of any device problems, technical failures, or operational difficulties encountered with the ES Scanner system during surgery.
Time frame: Intraoperative. Recorded in real-time during device use.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.